2. Protein Tyrosine Kinase/RTK Apoptosis Cell Cycle/DNA Damage JAK/STAT Signaling
  3. VEGFR Apoptosis Topoisomerase EGFR
  4. EGFR/VEGFR2-IN-13

EGFR/VEGFR2-IN-13 是一种多靶点抑制剂，对 VEGFR-2 的 IC50 为 0.98 µM，对 EGFR 的 IC50 为 1.01 µM，对拓扑异构酶 II (topoisomerase II) 的 IC50 为 1.94 µM。EGFR/VEGFR2-IN-13 可诱导肿瘤细胞细胞周期阻滞和凋亡 (apoptosis)。EGFR/VEGFR2-IN-13 作为抗癌剂，对癌细胞具有细胞毒性。EGFR/VEGFR2-IN-13 可用于乳腺癌、结肠癌、肝癌的相关研究。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

EGFR/VEGFR2-IN-13

EGFR/VEGFR2-IN-13 Chemical Structure

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
50 mg   询价  
100 mg   询价  
250 mg   询价  

* Please select Quantity before adding items.

Customer Review

EGFR/VEGFR2-IN-13 相关抗体

Top Publications Citing Use of Products

查看 VEGFR 亚型特异性产品:

查看所有亚型
VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

查看 Topoisomerase 亚型特异性产品:

查看所有亚型
Topoisomerase Topo I Topo II DNA gyrase

查看 EGFR 亚型特异性产品:

查看所有亚型
EGFR/ErbB1/HER1 ErbB2/HER2 ErbB3/HER3 ErbB4/HER4

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

EGFR/VEGFR2-IN-13 is a multi-target inhibitor, with an IC50 of 0.98 µM against VEGFR-2, 1.01 µM against EGFR, and 1.94 µM against topoisomerase II. EGFR/VEGFR2-IN-13 induces cell cycle arrest and apoptosis in tumor cells. As an anticancer agent, EGFR/VEGFR2-IN-13 exhibits cytotoxicity against cancer cells. EGFR/VEGFR2-IN-13 can be used in research related to breast cancer, colon cancer, and liver cancer[1].

IC50 & Target[1]

VEGFR-2

 

Topoisomerase II

 

体外研究
(In Vitro)

EGFR/VEGFR2-IN-13 (compound 16) (48 h) 可抑制 MCF-7、HCT-116 和 HepG-2 癌细胞系的增殖，其 IC50 值分别为 3.78 µM、4.27 µM 和 4.79 µM[1]。
EGFR/VEGFR2-IN-13 (3.78 µM; 72 h) 可诱导 MCF-7 细胞以凋亡作为主要细胞死亡方式[1]。
EGFR/VEGFR2-IN-13 (3.78 µM; 72 h) 可诱导 MCF-7 细胞发生 G0/G1 期细胞周期阻滞[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

EGFR/VEGFR2-IN-13 相关抗体:

Apoptosis Analysis[1]

Cell Line: MCF-7
Concentration: 3.78 µM
Incubation Time: 72 h
Result: Induced a total apoptosis rate of 32.79% (19.39% early apoptotic cells, 8.33% late apoptotic cells) and a necrosis rate of 5.07%, compared to 3.12% total apoptosis and 2.34% necrosis in untreated control cells.

Cell Cycle Analysis[1]

Cell Line: MCF-7
Concentration: 3.78 µM
Incubation Time: 72 h
Result: Resulted in accumulation of 65.88% of cells in the G0/G1 phase, 29.67% in the S phase, and 4.43% in the G2/M phase.
分子量

500.63

Formula

C24H28N4O4S2
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

EGFR/VEGFR2-IN-13 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

EGFR/VEGFR2-IN-13VEGFRApoptosisTopoisomeraseEGFRVascular endothelial growth factor receptorEpidermal growth factor receptorErbB-1HER1liver cancertopoisomerase IIbreast cancerearly apoptosisMCF-7HCT-116colon cancerG0/G1 cell cycle arrestVEGFR-2Inhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
EGFR/VEGFR2-IN-13
目录号：
HY-183090
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z